

4.0.03 DOC Cmte minutes

VTE Diseases Committee meeting

Date: 10/09/2018

Location: NICE – Manchester

Minutes: Final



| Committee members present: | |
|-----------------------------------|--------------------------------------|
| Susan Bewley (SB) (Chair) | Present for all |
| Frances Akor (FA) | Present until partway through item 6 |
| Julia Anderson (JA) | Present for all |
| Michelle Greene (MG) | Present for all |
| Sam Hare (SH) | Present for all |
| Carol Hooper (CH) | Present for all |
| Nigel Langford (NL) | Present for all |
| Terry McCormack (TM) | Present for all |
| Simon McPherson (SM) | Present from item 3 |
| Karen Sheares (KS) | Present until partway through item 6 |
| Hazel Trender (HT) | Present for all |
| Astrid Ullrich-Boereboom (AU) | Present for all |

| In attendance: | | |
|-------------------------|---|--|
| Elizabeth Barrett (EB) | NICE – Information Specialist | Until partway through item 4 |
| Kathryn Hopkins (KH) | NICE – Technical Adviser | Present for all |
| Thomas Jarratt (TJ) | NICE – Technical Analyst | Present for all |
| Ben Johnson (BJ) | NICE – Health Economist | Present for all |
| Justine Karpusheff (JK) | NICE – Guidelines Commissioning Manager | Present for items 1 to part of 3, and from partway through item 4. |
| Bernadette Li (BL) | NICE – Technical Adviser (HE) | Present for all |
| Vonda Murray (VM) | NICE – Project Manager | Present for all |

4.0.03 DOC Cmte minutes

Apologies:

| | |
|--------------------|---------------------------|
| Daniel Horner (DH) | Committee member |
| Susan Spiers | NICE – Associate Director |

Obsever:

| | | |
|-------------|-------------------------------|--------------------------------------|
| Mike Raynor | NICE – Information Specialist | Present until partway through item 4 |
|-------------|-------------------------------|--------------------------------------|

1. Introductions and guideline committee working

The Chair welcomed the Committee members and attendees to the fourth committee meeting on VTE diseases. The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received from those listed above.

The minutes were reviewed from Gcomm 3; Tuesday 31st July 2018. The minutes were agreed to be an accurate record. The Chair outlined the objectives of the meeting; 2 review questions, along with a discussion in the afternoon on evidence for pharmacological treatments and health economics section.

The Chair asked everyone to verbally declare any interests. The following new interest was declared:

| Name | Job title | Declarations of Interest | Type of interest | Decision taken |
|--------------|------------|--|------------------|--|
| Frances Akor | Pharmacist | Consultancy fee received from Sanofi field force regarding an educational talk on; anticoagulation, thrombolysis and ivc filters. Also spoke about follow up and handover/ transfer of care. | Direct financial | Partial exclusion – RQ3.1, 3.2, 1.3, 2.4 (GComm5) |

4.0.03 DOC Cmte minutes

The DOI register was made available to the Chair, and committee. The Chair reviewed the DOI register. The DOI's were considered by the Chair, it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Clinical introduction to Review Question 2.1

TM provided a clinical introduction what the pulmonary embolism rule-out criteria (PERC) is for people suspected PE

3. Review Question 2.1: In people with suspected PE, what is the diagnostic accuracy of the pulmonary embolism rule-out criteria (PERC)?

- ❖ Clinical evidence presentation and discussion
- ❖ Health economic evidence presentation and discussion
- ❖ Agree evidence statements
- ❖ Draft recommendations

KH provided a summary of the search protocol, including the inclusion and exclusion criteria. KH provided an overview of the evidence for; what is the diagnostic accuracy of the pulmonary embolism rule-out criteria (PERC), in people with suspected PE. The committee agreed the evidence statement for the review question.

BJ provided the health economic evidence for the review question. The committee discussed the clinical and health economic evidence presented, and asked KH and BJ questions. The committee discussed and agreed recommendations accordingly.

4. Review Question 4.1: Do investigations for cancer in people with unprovoked VTE improve outcomes (morbidity and mortality)?

- ❖ Clinical evidence presentation and discussion
- ❖ Health economic evidence presentation and discussion
- ❖ Agree evidence statements
- ❖ Draft recommendations

TJ outlined the agreed protocol, and explained the evidence base, before presenting the clinical evidence found on does investigations for cancer in people with unprovoked VTE improve outcomes (morbidity and mortality). The committee agreed the evidence statement for the review question.

BJ presented to the committee the health economic evidence for the review question. The committee discussed the presented evidence and agreed recommendations accordingly.

5. Discussion on evidence for pharmacological treatments review questions

4.0.03 DOC Cmte minutes

Due to time constraints the committee agreed to discuss this item at a later date.

6. Health economics modelling update

BJ discussed developments with the health economic model being constructed with the committee.

7. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting: Monday 29th and Tuesday 30th October 2018

Location of next meeting: NICE - London